LIXTE Shares Are Trading Higher After the Company Announced the Publication of Pre-clinical Data on Its Lead Clinical Compound, LB-100
LIXTE宣佈公佈其主要臨床化合物 LB-100 的臨床前數據後,該公司股價走高
LIXTE Shares Are Trading Higher After the Company Announced the Publication of Pre-clinical Data on Its Lead Clinical Compound, LB-100
LIXTE宣佈公佈其主要臨床化合物 LB-100 的臨床前數據後,該公司股價走高
使用瀏覽器的分享功能,分享給你的好友吧